Fda's oncologic drugs advisory committee decision on checkpoint inhibitors substantiates potential of cel-sci's multikine® to address major treatment gap for pd-l1 negative cancer patients

Vienna, va.--(business wire)---- $cvm #multikine--fda's odac decision on checkpoint inhibitors substantiates potential of multikine to address major treatment gap for pd-l1 negative cancer patients.
SCI Ratings Summary
SCI Quant Ranking